{"id":11739,"date":"2025-07-21T18:29:00","date_gmt":"2025-07-21T12:59:00","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=11739"},"modified":"2025-10-27T12:16:04","modified_gmt":"2025-10-27T06:46:04","slug":"anthem-biosciences-ipo","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/anthem-biosciences-ipo\/","title":{"rendered":"Anthem Biosciences IPO: Shares Make Strong Debut with 28.36% Premium to IPO Price"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]Anthem Biosciences<\/a>, a prominent contract research, development, and manufacturing organisation (CRDMO), has made a remarkable debut on the Indian stock exchanges. The company\u2019s initial public offering (IPO)<\/a> was keenly awaited, and its listing on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) today, on 21 July 2025, reflects strong investor interest.<\/span>\u00a0<\/span><\/p>\n

<\/span>Stock Performance on Listing Day<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n

On its d<\/span>ebut day, Anthem Biosciences saw a solid opening, with its shares listed at \u20b9723.05 each on the NSE, marking a 26.85% rise from the IPO price of \u20b9570. The company\u2019s stock continued its upward trajectory and closed at \u20b9731.65 on the NSE, a 28.36% premium over the issue price. On the BSE, the stock closed at \u20b9730.35, a 28.13% premium, signalling investor optimism in the company\u2019s future.<\/span>\u00a0<\/span><\/p>\n

<\/span>Anthem Biosciences IPO Details<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n

Th<\/span>e IPO of Anthem Biosciences opened for subscription on 14 July 2025 and closed on 16 July 2025. The IPO was well-received by the market, with the subscription closing at 63.86 times on the final day. The company set the price band between \u20b9540 and \u20b9570 per share for the public offering. The listing today was highly anticipated, as experts predicted significant listing gains, which materialised with the stock debuting well above the issue price.<\/span>\u00a0<\/span><\/p>\n

<\/span>Company Profile<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n

<\/span>Listing and Market Sentiment<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n

The strong perform<\/span>ance of Anthem Biosciences on its listing day is a positive indicator of market confidence in the company\u2019s future growth potential. Investors are cle<\/span>arly optimistic about the firm\u2019s prospects, driven by its strong market presence and significant growth in the CRDMO sector.<\/span>\u00a0<\/span><\/p>\n

<\/span>Conclusion<\/span><\/b>\u00a0<\/span><\/span><\/h2>\n

Anthem <\/span>Biosciences\u2019 debut on the stock exchanges today is a clear sign of strong market confidence. The 28.36% premium to its IPO price reflects the solid demand for its shares, and the positive investor sentiment surrounding the company\u2019s growth strategy. As Anthem Biosciences continues to expand its footprint in drug discovery, development, and manufacturing, it is expected to make further strides in the biotechnology industry.<\/span>\u00a0<\/span><\/p>\n

Rate this article<\/h6>\n

With today\u2019s strong listing, Anthem Biosciences is now poised to leverage the capital raised through its IPO to fuel future expansion and innovation in the pharmaceutical space. This debut marks a significant milestone in the company\u2019s journey<\/span> on the Indian stock market<\/a>.<\/span>\u00a0<\/span>[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Anthem Biosc<\/span>iences is a contract research, development, and manufacturing organisation (CRDMO) that focuses on driving innovation in the pharmaceutical sector<\/a>. The company provides a wide range of services, covering everything from drug discovery to development and manufacturing. Anthem\u2019s strategic emphasis on technology and innovation positions it as a key player in the global biotechnology and pharmaceutical industries.<\/span>\u00a0<\/span><\/p>\n